Synthesis of Potent Leukotriene A<sub>4</sub> Hydrolase Inhibitors. Identification of 3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid
作者:Thomas D. Penning、Mark A. Russell、Barbara B. Chen、Helen Y. Chen、Chi-Dean Liang、Matthew W. Mahoney、James W. Malecha、Julie M. Miyashiro、Stella S. Yu、Leslie J. Askonas、James K. Gierse、Elizabeth I. Harding、Maureen K. Highkin、James F. Kachur、Suzanne H. Kim、Doreen Villani-Price、E. Yvonne Pyla、Nayereh S. Ghoreishi-Haack、Walter G. Smith
DOI:10.1021/jm0200916
日期:2002.8.1
related to screening hit SC-22716 (1, 1-[2-(4-phenylphenoxy)ethyl]pyrrolidine) and resulted in the identification of potent, orally active inhibitors such as 2. Additional structure-activity relationship studies around this structural class resulted in the identification of a series of alpha-, beta-, and gamma-amino acid analogues that are potent inhibitors of the LTA(4) hydrolase enzyme and demonstrated
白三烯B(4)(LTB(4))是一种强效的促炎介质,参与多种疾病的发病机理,包括炎症性肠病,牛皮癣,类风湿性关节炎和哮喘。LTA(4)水解酶代表了在这些疾病状态下进行药物干预的诱人靶标,因为该酶的作用是LTB(4)生产中的限速步骤。我们先前的工作重点是探索与筛选热门SC-22716(1,1- [2-(4-苯基苯氧基)乙基]吡咯烷)有关的一系列类似物,并确定了有效的口服活性抑制剂,例如2 。围绕该结构类别进行的其他结构-活性关系研究导致鉴定出一系列α-,β-,和γ-氨基酸类似物,它们是LTA(4)水解酶的有效抑制剂,在小鼠离体全血LTB(4)生产测定中显示出良好的口服活性。描述了导致鉴定临床候选SC-57461A(8d,3- [甲基[3- [4-(苯基甲基)苯氧基]丙基]氨基]丙酸的努力)。